Drug Innovation
Blog
Learn how drug price controls hurt patients, innovation
Senator Sanders’ Price Controls Will Harm Patients
In a patently politicized press release, Senator Bernie Sanders (I-VT) who is Chairman of the Senate Health, Education, Labor, and Pensions (HELP) Committee, claims that the U.S. price of Ozempic is too high. As evidence, he cites generic companies that claim they can sell Ozempic for less than $100 a ...
Commentary
Read the latest on Biden administration's drug price controls
Drug Price Controls Underperform, Unworkable
According to the White House, the program will save the federal government an estimated $6 billion in 2026, the first year the new prices will be in effect, while reducing costs for seniors by $1.5 billion. Those figures might seem impressive. But they are almost certainly inflated. In fact, it’s ...
Commentary
Learn about the damage from lawsuit abuse
Tort Abuses Threat To Innovation And Product Availability
Not only is continued invention necessary for expanding our prosperity, but it is also key for mitigating problems such as global climate change or finding new technologies and treatments for troubling health conditions. Take the state and municipal lawsuits being filed against energy companies as an example. When announcing his ...
Commentary
This Bipartisan Bill Would Upend America’s Pharmaceutical Industry
Vice President Kamala Harris and Minnesota Governor Tim Walz have pivoted hard to the center in recent weeks in their bid for the White House. But their records indicate that they’d launch even more government intervention in the healthcare market. Harris was the most progressive member of the Senate during ...
Blog
Read about Biden drug price control plan
The Damage from Price Controls on Pharmaceuticals Begins
The federal government has announced the long-awaited results from the 2022 Inflation Reduction Act’s (IRA) drug price negotiations.[1] The Biden Administration has been crowing that they have achieved “a historic moment that will help lower prescription drug prices for millions of people across America.” Nothing could be further from the ...
Commentary
Scope-of-practice laws put patients in the crosshairs
New research appears to have found the proverbial “free lunch” economists have long been searching for. States that grant nurse practitioners “full practice authority” — that authorize them to provide care independently, without the supervision of a physician or other provider — reduce total healthcare costs for people with diabetes ...
Commentary
Pending Government Drug Pricing Will Harm Seniors’ Care And Budgets
Any day now, the Biden administration will publish the prices it has set for ten drugs covered by Medicare’s Part D prescription drug benefit. These price controls will provide “meaningful financial relief for millions of people with Medicare,” administration officials say. Many seniors are about to see just how false that ...
Commentary
The Anti-Competitive Middlemen Harming Pharmacies And Patients
Astonishing drug innovations are improving the lives of patients including those living with cancer and autoimmune disorders. These innovations also expose the payment system’s fundamental flaws. The Federal Trade Commission’s (FTC) recently released interim report on pharmacy middlemen demonstrates that these flaws impose a high cost on patients and neighborhood pharmacies. These ...
Commentary
Read the latest on pharmaceutical benefit managers
Legislation Urgently Needed to Rein In Pharmacy Benefit Mgrs.
The U.S. House Committee on Oversight and Accountability held a hearing last month with the CEOs of the nation’s three largest pharmacy benefit managers: CVS Caremark, Express Scripts, and OptumRx. The hearing coincided with a new report from the committee on the outsized role these prescription-drug middlemen play in determining what people pay for ...
Commentary
Read the latest on the 340B Drug Pricing Program
Reforming 340B to Serve the Interests of Patients, Not Institutions
By Anthony M. DiGiorgio, DO, MHA and Wayne Winegarden, PhD Enacted by the US Congress in 1992 to help entities serving lower-income and uninsured patients stretch their resources, the 340B Drug Pricing Program mandated drug companies give large discounts to covered entities (CEs). Judging the program on its outcomes, not its intentions, ...
Learn how drug price controls hurt patients, innovation
Senator Sanders’ Price Controls Will Harm Patients
In a patently politicized press release, Senator Bernie Sanders (I-VT) who is Chairman of the Senate Health, Education, Labor, and Pensions (HELP) Committee, claims that the U.S. price of Ozempic is too high. As evidence, he cites generic companies that claim they can sell Ozempic for less than $100 a ...
Read the latest on Biden administration's drug price controls
Drug Price Controls Underperform, Unworkable
According to the White House, the program will save the federal government an estimated $6 billion in 2026, the first year the new prices will be in effect, while reducing costs for seniors by $1.5 billion. Those figures might seem impressive. But they are almost certainly inflated. In fact, it’s ...
Learn about the damage from lawsuit abuse
Tort Abuses Threat To Innovation And Product Availability
Not only is continued invention necessary for expanding our prosperity, but it is also key for mitigating problems such as global climate change or finding new technologies and treatments for troubling health conditions. Take the state and municipal lawsuits being filed against energy companies as an example. When announcing his ...
This Bipartisan Bill Would Upend America’s Pharmaceutical Industry
Vice President Kamala Harris and Minnesota Governor Tim Walz have pivoted hard to the center in recent weeks in their bid for the White House. But their records indicate that they’d launch even more government intervention in the healthcare market. Harris was the most progressive member of the Senate during ...
Read about Biden drug price control plan
The Damage from Price Controls on Pharmaceuticals Begins
The federal government has announced the long-awaited results from the 2022 Inflation Reduction Act’s (IRA) drug price negotiations.[1] The Biden Administration has been crowing that they have achieved “a historic moment that will help lower prescription drug prices for millions of people across America.” Nothing could be further from the ...
Scope-of-practice laws put patients in the crosshairs
New research appears to have found the proverbial “free lunch” economists have long been searching for. States that grant nurse practitioners “full practice authority” — that authorize them to provide care independently, without the supervision of a physician or other provider — reduce total healthcare costs for people with diabetes ...
Pending Government Drug Pricing Will Harm Seniors’ Care And Budgets
Any day now, the Biden administration will publish the prices it has set for ten drugs covered by Medicare’s Part D prescription drug benefit. These price controls will provide “meaningful financial relief for millions of people with Medicare,” administration officials say. Many seniors are about to see just how false that ...
The Anti-Competitive Middlemen Harming Pharmacies And Patients
Astonishing drug innovations are improving the lives of patients including those living with cancer and autoimmune disorders. These innovations also expose the payment system’s fundamental flaws. The Federal Trade Commission’s (FTC) recently released interim report on pharmacy middlemen demonstrates that these flaws impose a high cost on patients and neighborhood pharmacies. These ...
Read the latest on pharmaceutical benefit managers
Legislation Urgently Needed to Rein In Pharmacy Benefit Mgrs.
The U.S. House Committee on Oversight and Accountability held a hearing last month with the CEOs of the nation’s three largest pharmacy benefit managers: CVS Caremark, Express Scripts, and OptumRx. The hearing coincided with a new report from the committee on the outsized role these prescription-drug middlemen play in determining what people pay for ...
Read the latest on the 340B Drug Pricing Program
Reforming 340B to Serve the Interests of Patients, Not Institutions
By Anthony M. DiGiorgio, DO, MHA and Wayne Winegarden, PhD Enacted by the US Congress in 1992 to help entities serving lower-income and uninsured patients stretch their resources, the 340B Drug Pricing Program mandated drug companies give large discounts to covered entities (CEs). Judging the program on its outcomes, not its intentions, ...
